Compare EXFY & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXFY | ENTX |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 147.4M |
| IPO Year | 2021 | 2015 |
| Metric | EXFY | ENTX |
|---|---|---|
| Price | $2.32 | $2.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.50 | ★ $9.00 |
| AVG Volume (30 Days) | 1.1M | ★ 3.6M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $142,101,000.00 | $42,000.00 |
| Revenue This Year | $0.42 | N/A |
| Revenue Next Year | $0.11 | N/A |
| P/E Ratio | ★ N/A | $13.05 |
| Revenue Growth | ★ 2.06 | N/A |
| 52 Week Low | $0.69 | $0.91 |
| 52 Week High | $2.81 | $4.20 |
| Indicator | EXFY | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.10 | 57.95 |
| Support Level | $1.32 | $1.10 |
| Resistance Level | N/A | $3.22 |
| Average True Range (ATR) | 0.20 | 0.32 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 51.42 | 13.81 |
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.